CVS Health (NYSE:CVS) Issues FY 2026 Earnings Guidance

CVS Health (NYSE:CVS) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 5.940-6.140 for the period, compared to the consensus earnings per share estimate of 7.160. The company issued revenue guidance of -.

Analysts Set New Price Targets

A number of research firms have recently commented on CVS. Wells Fargo & Company lowered their target price on CVS Health from $103.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, November 13th. UBS Group reissued an “outperform” rating on shares of CVS Health in a research note on Wednesday, December 10th. Evercore upped their target price on shares of CVS Health from $85.00 to $95.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Bank of America dropped their price target on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research report on Tuesday, January 27th. Finally, Morgan Stanley upped their price objective on CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Nineteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $94.82.

CVS Health Stock Down 2.9%

Shares of NYSE CVS opened at $76.06 on Tuesday. CVS Health has a 1 year low of $53.36 and a 1 year high of $85.15. The firm has a 50-day simple moving average of $78.56 and a two-hundred day simple moving average of $75.87. The company has a market cap of $96.55 billion, a P/E ratio of 200.16, a PEG ratio of 0.72 and a beta of 0.50. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63.

CVS Health (NYSE:CVS) last released its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.10. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The firm had revenue of $105.69 billion for the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Research analysts anticipate that CVS Health will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Thursday, January 22nd. CVS Health’s dividend payout ratio (DPR) is 700.00%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q4 beat: CVS reported adjusted EPS of $1.09 (vs. $0.99 expected) and revenue of $105.69B (above estimates), showing stronger sales and prescription volume that helped beat Street forecasts. Press Release
• Positive Sentiment: Turnaround traction: Management says the turnaround is taking hold — revenue rose ~8% in Q4 and operational changes at Pharmacy/Aetna are improving approvals and flow, which supports margin recovery and longer‑term profit potential. CVS Health’s turnaround is paying off
• Neutral Sentiment: Operational metrics: CVS reported record FY revenue (~$402.1B) and generated $10.6B in operating cash flow and completed a shift to cost‑based reimbursement — positive fundamentals but not an immediate catalyst. PR Newswire: Q4 and FY results
• Negative Sentiment: Guidance miss: CVS set FY‑2026 EPS guidance at $5.94–$6.14, materially below the consensus (~$7.16), which is the primary reason for the stock weakness despite the quarter’s beats.
• Negative Sentiment: Medicare/rate risk: Analysts and coverage pieces highlight ongoing concerns about Medicare reimbursement proposals and rate pressure for the insurance business, which could weigh on margins and investor sentiment. CVS Stock Falls After Earnings Beat
• Negative Sentiment: Regulatory/market sensitivity: Commentary ahead of the print flagged Medicare proposals as a risk; any further clarity that reduces reimbursement or increases uncertainty could prolong the stock’s underperformance. MSN: Under Pressure From Medicare Proposal

Institutional Investors Weigh In On CVS Health

Several large investors have recently added to or reduced their stakes in CVS. State Street Corp boosted its position in CVS Health by 0.3% during the 3rd quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock valued at $4,443,357,000 after acquiring an additional 149,701 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in shares of CVS Health by 5.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 7,855,845 shares of the pharmacy operator’s stock worth $541,903,000 after purchasing an additional 385,806 shares during the last quarter. Amundi boosted its position in CVS Health by 95.3% during the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after purchasing an additional 3,637,943 shares in the last quarter. Wellington Management Group LLP grew its stake in CVS Health by 391.6% in the third quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock valued at $477,273,000 after purchasing an additional 5,042,816 shares during the last quarter. Finally, Raymond James Financial Inc. raised its holdings in CVS Health by 4.4% in the second quarter. Raymond James Financial Inc. now owns 3,191,584 shares of the pharmacy operator’s stock worth $220,155,000 after purchasing an additional 133,875 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.